SGLT2 Inhibitors and External Genital Infection in Male Patients With Type 2 Diabetes.

ABSTRACT:

Importance

New medications for type 2 diabetes (T2D) control, such as sodium-glucose cotransporter-2 inhibitors (SGLT2Is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), have emerged. However, the US Food and Drug Administration has warned about potential risks of Fournier gangrene, a severe genital infection associated with SGLT2I use.

Objective

To determine comparative risks of male external genital infections (MEGIs) in adult male patients with T2D treated with SGLT2Is.

Design, setting, and participants

A population-based cohort study analyzing Taiwan's National Health Insurance Research Database was conducted to evaluate the MEGI risk in adult male patients with T2D newly treated with SGLT2Is between January 1, 2009, and December 31, 2020. Patients newly

SUBMITTER: Cheng TH 

PROVIDER: S-EPMC12481227 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature